<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03506893</url>
  </required_header>
  <id_info>
    <org_study_id>38RC17.109</org_study_id>
    <nct_id>NCT03506893</nct_id>
  </id_info>
  <brief_title>Medical-economic Evaluation of the Care of Refractory Ascites by Implantation of Alfapump® Device in Cirrhotic Patients</brief_title>
  <acronym>ARIAPUMP</acronym>
  <official_title>Medical-economic Evaluation of the Care of Refractory Ascites by Implantation of Alfapump® Device in Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that the Alfapump® strategy would be more effective in terms of QALYs
      generated , and that the cost of Alfapump® device and its implantation will be totally or
      partially offset by the reduction in the number of evacuating parentheses performed and the
      reduction in the number of complications in patients with refractory ascites awaiting liver
      transplantation or not. On the other hand, given the difference in the clinical profiles of
      these two populations (whether or not they are awaiting transplantation), these two
      populations will be study separately

      Evaluation of the medical-economic impact at 1 year of the two therapeutic strategies:
      implantation of Alfapump® versus repeated evacuating paracentesis in cirrhotic patients with
      refractory ascites without scheduled liver transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Refractory ascites is one of the complications associated with portal hypertension in the
      cirrhotic patient. To date, its treatment consists of evacuating punctures, performed in day
      hospitalisation, whose frequency is adapted to the rate of ascites synthetis. Paracentesis,
      which does not affect the mechanisms of ascites formation, contributes to protein catabolism
      and undernutrition. They also have an inconvenience linked to the gesture, making frequent
      hospital stays necessary. For all these reasons, the patient's quality of life is diminished.
      The Alfapump® system is a new method for the treatment of refractory ascites. It is a
      completely internalized medical device, implanted under the skin, which mobilizes ascites
      from the peritoneal cavity to the bladder, where ascites is eliminated by urinary tract.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 25, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of medical-economic impact at 1 year of 2 strategies: implantation of Alfapump® device versus repeated evacuating paracentesis (reference treatment) in cirrhotic patients with refractory ascites without programmed liver transplantation.</measure>
    <time_frame>1 year</time_frame>
    <description>Incremental cost-utility ratio (ICER) from societal perspective.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the clinical impact at 6 and 12 months of Alfapump® versus repeated evacuating paracentesis in cirrhotic patients with refractory ascites WITHOUT programmed liver transplantation.</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>Evaluation of the paracentesis-free survival, cirrhosis and device-related adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the clinical impact at 6 and 12 months of Alfapump® versus repeated evacuating paracentesis in cirrhotic patients with refractory ascites WITH programmed liver transplantation.</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>Evaluation of the paracentesis-free survival, cirrhosis and device-related adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the economic impact at 6 and 12 months of Alfapump® versus repeated evacuating paracentesis in cirrhotic patients with refractory ascites WITH programmed liver transplantation.</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>Incremental cost-utility ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the clinical impact at 2 years of Alfapump® versus repeated evacuating paracentesis (prospective observational study).</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of paracentesis-free survival, cirrhosis and device-related adverse events. We will analyse separately patients WITH and WITHOUT programmed liver transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the economic impact at 2 years of Alfapump® versus repeated evacuating paracentesis (prospective observational study).</measure>
    <time_frame>2 years</time_frame>
    <description>Incremental cost-utility ratio. We will analyse separately patients WITH and WITHOUT programmed liver transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Budget impact Analysis from the point of view of French health insurance, at 3 and 5 years.</measure>
    <time_frame>3 and 5 years</time_frame>
    <description>Economic consequences of the introduction of the Alfapump® device in the management strategies of cirrhotic patients presenting a refractory ascites.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Ascites</condition>
  <condition>Paracentesis</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Alphapump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alfapump® device implantation under general anesthesia (30-45 minutes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ascites puncture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iterative paracentesis compensated for by albumin infusions in ambulatory care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alphapump</intervention_name>
    <description>Alfapump® device: a completely internalized medical device, implanted under the skin, which mobilizes ascites from the peritoneal cavity to the bladder where they are eliminated by the urinary tract.
Medical device marked CE, used in the indication provided for marking</description>
    <arm_group_label>Alphapump</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ascites puncture</intervention_name>
    <description>Hospitalizations for evacuating ascites are performed at least twice a month and can be up to 2 times a week. A clinical and biological examination is carried out at each visit.</description>
    <arm_group_label>Ascites puncture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with refractory ascites who has had a minimum of 8 paracentesis in the last 3
             months.

          -  Patient with an estimated life expectancy of at least 6 months on the day of
             inclusion.

          -  Patient with contraindication to the application of a TIPS or who has expressed a
             refusal of the procedure or a non-functional TIPS

          -  Patient affiliated with or in receipt of social security

          -  Informed and written consent signed by the patient.

        Exclusion Criteria:

          -  Local or systemic infection in the month preceding the procedure

          -  Hepatocellular carcinoma with palliative care

          -  MELD Score &gt; 18

          -  Child Pugh C Score &gt; 10

          -  Creatinine Clearance &lt; 50 ml/mn

          -  Digestive hemorrhage or episode of hepatic encephalopathy within two weeks prior to
             device insertion

          -  Contraindication to general anesthesia

          -  Contraindication to implant surgery of the device:

               -  Obstructive urological impairment

               -  Partitioning of ascites

               -  Coagulopathy

          -  Persons referred to in Articles L1121-5 to L1121-8 of the CSP (corresponding to all
             protected persons: pregnant woman, parturient, breastfeeding mother, person deprived
             of liberty by judicial or administrative decision, person subject to a legal
             protection measure).

          -  Patient currently participating in other clinical research or who participated in a
             clinical trial within one month prior to inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Noelle HILLERET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra DAVID-TCHOUDA, MD</last_name>
    <phone>+33 476 76 71 86</phone>
    <email>sdavidtchouda@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandrine MASSICOT</last_name>
    <phone>+33 476 76 88 60</phone>
    <email>smassicot@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amiens-Picardie University Hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric NGUYEN-KHAC, PhD</last_name>
      <email>Nguyen-Khac.Eric@chu-amiens.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emilien COLIN</last_name>
      <phone>+333 22 08 88 67</phone>
      <email>colin.emilien@chu-amiens.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Jean MINJOZ Univesity Hospital</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry THEVENOT, PhD</last_name>
      <email>tthevenot@chu-besancon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emilie MUEL</last_name>
      <phone>+333 81 66 84 96</phone>
      <email>emuel@chu-besancon.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Haut-Lévêque Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victor DE LEDINGHEN, PhD</last_name>
      <email>victor.deledinghen@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Maude CHARBONNIER</last_name>
      <phone>+335 57 65 63 11</phone>
      <email>maude.charbonnier@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beaujon Hospital</name>
      <address>
        <city>Clichy la garenne</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire FRANCOZ, MD</last_name>
      <email>claire.francoz@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa ESNAULT</last_name>
      <phone>+33 140 87 50 64</phone>
      <email>vanessa.esnault@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Noelle HILLERET, MD</last_name>
      <phone>+334 76 76 62 57</phone>
      <email>mnhilleret@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LA PITIE SALPETRIERE Univesity Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique THABUT</last_name>
      <email>Dominique.thabut@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Florence BERGERON</last_name>
      <email>florence.bergeron@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe BUREAU, PhD</last_name>
      <phone>+335 61 77 22 63</phone>
      <email>Bureau.c@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bellot P, Welker MW, Soriano G, von Schaewen M, Appenrodt B, Wiest R, Whittaker S, Tzonev R, Handshiev S, Verslype C, Moench C, Zeuzem S, Sauerbruch T, Guarner C, Schott E, Johnson N, Petrov A, Katzarov K, Nevens F, Zapater P, Such J. Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol. 2013 May;58(5):922-7. doi: 10.1016/j.jhep.2012.12.020. Epub 2013 Jan 11.</citation>
    <PMID>23318604</PMID>
  </reference>
  <reference>
    <citation>Bureau C, Adebayo D, Chalret de Rieu M, Elkrief L, Valla D, Peck-Radosavljevic M, McCune A, Vargas V, Simon-Talero M, Cordoba J, Angeli P, Rosi S, MacDonald S, Malago M, Stepanova M, Younossi ZM, Trepte C, Watson R, Borisenko O, Sun S, Inhaber N, Jalan R. Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. J Hepatol. 2017 Nov;67(5):940-949. doi: 10.1016/j.jhep.2017.06.010. Epub 2017 Jun 21. Erratum in: J Hepatol. 2018 Jan 29;:.</citation>
    <PMID>28645737</PMID>
  </reference>
  <reference>
    <citation>Stirnimann G, Berg T, Spahr L, Zeuzem S, McPherson S, Lammert F, Storni F, Banz V, Babatz J, Vargas V, Geier A, Stallmach A, Engelmann C, Trepte C, Capel J, De Gottardi A. Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Aliment Pharmacol Ther. 2017 Nov;46(10):981-991. doi: 10.1111/apt.14331. Epub 2017 Sep 21.</citation>
    <PMID>28940225</PMID>
  </reference>
  <reference>
    <citation>Solà E, Solé C, Ginès P. Management of uninfected and infected ascites in cirrhosis. Liver Int. 2016 Jan;36 Suppl 1:109-15. doi: 10.1111/liv.13015. Review.</citation>
    <PMID>26725907</PMID>
  </reference>
  <reference>
    <citation>Thomas MN, Sauter GH, Gerbes AL, Stangl M, Schiergens TS, Angele M, Werner J, Guba M. Automated low flow pump system for the treatment of refractory ascites: a single-center experience. Langenbecks Arch Surg. 2015 Dec;400(8):979-83. doi: 10.1007/s00423-015-1356-1. Epub 2015 Nov 13.</citation>
    <PMID>26566989</PMID>
  </reference>
  <reference>
    <citation>Stepanova M, Nader F, Bureau C, Adebayo D, Elkrief L, Valla D, Peck-Radosavljevic M, McCune A, Vargas V, Simon-Talero M, Cordoba J, Angeli P, Rossi S, MacDonald S, Capel J, Jalan R, Younossi ZM. Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. Qual Life Res. 2018 Jun;27(6):1513-1520. doi: 10.1007/s11136-018-1813-8. Epub 2018 Feb 19.</citation>
    <PMID>29460201</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2018</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory ascite</keyword>
  <keyword>pump system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

